Drug intelligence / Profile preview

SRRM2 BiTE

Development stage: Preclinical
Lead developer: Eximmium Biotechnologies
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SRRM2 BiTE is a preclinical-stage bispecific T-cell engager (BiTE) being developed by Eximmium and Zeno Therapeutics for the treatment of oncology indications. The therapeutic is designed to target Serine/arginine repetitive matrix protein 2 (SRRM2), a nuclear speckles protein involved in pre-mRNA splicing that is aberrantly translocated and exposed on the surface of cancer cells. By simultaneously binding to SRRM2 on tumor cells and CD3 on T cells, the bispecific antibody recruits and activates T cells to selectively promote tumor-cell killing.

Other names: SRRM2-BiTESRRM-2-BiTESRRM 2-BiTE

Targets

CD3 (T-cell surface glycoprotein CD3)SRRM2 (Serine/arginine repetitive matrix protein 2)

Beyond the preview

Go deeper on SRRM2 BiTE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRRM2 BiTE.

Explore the full profile